Listen
AVASTIN (bevacizumab), monoclonal antibody - OVARIAN CANCER
ONCOLOGY - Focus
Opinions on drugs -
Posted on
Oct 13 2016
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit
- AVASTIN has Marketing Authorisation in combination with carboplatin and paclitaxel in the first-line treatment of advanced stage epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
- The addition of bevacizumab to carboplatin and to paclitaxel has demonstrated a modest effect on progression-free survival, without impacting the overall survival, but with an addition of adverse events such as bleeding, arterial hypertension and gastrointestinal perforations compared to carboplatin and paclitaxel.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| minor |
- |
English version
Contact Us
Évaluation des médicaments
